Virtus LifeSci Biotech Clinical Trials ETF
19 hedge funds and large institutions have $6.02M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$387K | |
| 2 | +$57.8K | |
| 3 | +$18.8K | |
| 4 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
+$9.25K |
| 5 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$2.5K |
Top Sellers
| 1 | -$244K | |
| 2 | -$187K | |
| 3 | -$68.1K | |
| 4 |
Morgan Stanley
New York
|
-$11.6K |
| 5 |
LPL Financial
San Diego,
California
|
-$10.8K |